Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice

Annals of Neurology

Volumn 73, Issue 2, 2013, Pages 189-198

  Wang, Lixiang ^a   Fan, Wenying ^a   Cai, Ping ^a   Fan, Mengchen ^a   Zhu, Ximin ^a   Dai, Yiqin ^a   Sun, Chungang ^a   Cheng, Yannan ^a   Zheng, Ping ^a   Zhao, Bing Qiao ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT PROTEIN; RECOMBINANT VON WILLEBRAND FACTOR CLEAVING PROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; CEREBROSPINAL FLUID; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG SAFETY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; VASCULAR ENDOTHELIUM;

ADAM PROTEINS; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; MICE, INBRED C57BL; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT PROTEINS; RHO GTP-BINDING PROTEINS; STROKE; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84884211418     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23762     Document Type: Article

References (50)

1. Zivin JA,. Acute stroke therapy with tissue plasminogen activator (tPA) since it was approved by the U.S. Food and Drug Administration (FDA). Ann Neurol 2009; 66: 6-10.
2. Lansberg MG, Albers GW, Wijman CA,. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis 2007; 24: 1-10.
3. Wardlaw JM, Sandercock PA, Berge E,. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis. Stroke 2003; 34: 1437-1442.
4. Vivien D, Buisson A,. Serine protease inhibitors: novel therapeutic targets for stroke ? J Cereb Blood Flow Metab 2000; 20: 755-764.
5. Lo EH, Dalkara T, Moskowitz MA,. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003; 4: 399-415.
6. Nicole O, Docagne F, Ali C, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7: 59-64.
7. Wang YF, Tsirka SE, Strickland S, et al. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998; 4: 228-231.
8. Yepes M, Sandkvist M, Wong MK, et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 2000; 96: 569-576.
9. Wang X, Lee SR, Arai K, et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003; 9: 1313-1317.
10. Morancho A, Rosell A, Garcia-Bonilla L, Montaner J,. Metalloproteinase and stroke infarct size: role for anti-inflammatory treatment ? Ann N Y Acad Sci 2010; 1207: 123-133.
11. Cheng T, Petraglia AL, Li Z, et al. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med 2006; 12: 1278-1285.
12. Jian Liu K, Rosenberg GA,. Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic Biol Med 2005; 39: 71-80.
13. An J, Zhang C, Polavarapu R, et al. Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain. Blood 2008; 112: 2787-2794.
14. Dijkhuizen RM, Asahi M, Wu O, et al. Rapid breakdown of microvascular barriers and subsequent hemorrhagic transformation after delayed recombinant tissue plasminogen activator treatment in a rat embolic stroke model. Stroke 2002; 33: 2100-2104.
15. Kastrup A, Groschel K, Ringer TM, et al. Early disruption of the blood-brain barrier after thrombolytic therapy predicts hemorrhage in patients with acute stroke. Stroke 2008; 39: 2385-2387.
16. Sadler JE,. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112: 11-18.
17. Crawley JT, de Groot R, Xiang Y, et al. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood 2011; 118: 3212-3221.
18. Soejima K, Nakamura H, Hirashima M, et al. Analysis on the molecular species and concentration of circulating ADAMTS13 in Blood. J Biochem 2006; 139: 147-154.
19. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-4039.
20. Yamamoto K, de Waard V, Fearns C, Loskutoff DJ,. Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo. Blood 1998; 92: 2791-2801.
21. Bath PM, Blann A, Smith N, Butterworth RJ,. Von Willebrand factor, P-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. Platelets 1998; 9: 155-159.
22. Vergouwen MD, Bakhtiari K, van Geloven N, et al. Reduced ADAMTS13 activity in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab 2009; 29: 1734-1741.
23. Federici AB, Berkowitz SD, Zimmerman TS, Mannucci PM,. Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction. Blood 1992; 79: 38-44.
24. Zhao BQ, Chauhan AK, Canault M, et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 2009; 114: 3329-3334.
25. Fujioka M, Hayakawa K, Mishima K, et al. ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood 2010; 115: 1650-1653.
26. Su EJ, Fredriksson L, Geyer M, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 2008; 14: 731-737.
27. Zhao BQ, Wang S, Kim HY, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 2006; 12: 441-445.
28. Won SJ, Tang XN, Suh SW, et al. Hyperglycemia promotes tissue plasminogen activator-induced hemorrhage by increasing superoxide production. Ann Neurol 2011; 70: 583-590.
29. Poppe AY, Majumdar SR, Jeerakathil T, et al. Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis. Diabetes Care 2009; 32: 617-622.
30. Zhao BQ, Ikeda Y, Ihara H, et al. Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice. Blood 2004; 103: 2610-2616.
31. Patel KN, Soubra SH, Bellera RV, et al. Differential role of von Willebrand factor and P-selectin on microvascular thrombosis in endotoxemia. Arterioscler Thromb Vasc Biol 2008; 28: 2225-2230.
32. Cervia D, Catalani E, Dal Monte M, Casini G,. Vascular endothelial growth factor in the ischemic retina and its regulation by somatostatin. J Neurochem 2012; 120: 818-829.
33. Yepes M, Sandkvist M, Moore EG, et al. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003; 112: 1533-1540.
34. Zhang ZG, Zhang L, Jiang Q, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 2000; 106: 829-838.
35. Abumiya T, Yokota C, Kuge Y, Minematsu K,. Aggravation of hemorrhagic transformation by early intraarterial infusion of low-dose vascular endothelial growth factor after transient focal cerebral ischemia in rats. Brain Res 2005; 1049: 95-103.
36. Kanazawa M, Igarashi H, Kawamura K, et al. Inhibition of VEGF signaling pathway attenuates hemorrhage after tPA treatment. J Cereb Blood Flow Metab 2011; 31: 1461-1474.
37. Beck H, Acker T, Wiessner C, et al. Expression of angiopoietin-1, angiopoietin-2, and tie receptors after middle cerebral artery occlusion in the rat. Am J Pathol 2000; 157: 1473-1483.
38. Kilic E, Kilic U, Wang Y, et al. The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia. FASEB J 2006; 20: 1185-1187.
39. Bryan BA, Dennstedt E, Mitchell DC, et al. RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J 2010; 24: 3186-3195.
40. Yagita Y, Kitagawa K, Sasaki T, et al. Rho-kinase activation in endothelial cells contributes to expansion of infarction after focal cerebral ischemia. J Neurosci Res 2007; 85: 2460-2469.
41. Kleinschnitz C, De Meyer SF, Schwarz T, et al. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood 2009; 113: 3600-3603.
42. Bergmeier W, Chauhan AK, Wagner DD,. Glycoprotein Ibalpha and von Willebrand factor in primary platelet adhesion and thrombus formation: lessons from mutant mice. Thromb Haemost 2008; 99: 264-270.
43. Nieswandt B, Stoll G,. The smaller, the better: VWF in stroke. Blood 2010; 115: 1477-1478.
44. Hamann GF, Okada Y, del Zoppo GJ,. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab 1996; 16: 1373-1378.
45. Rodansky ES, Smith JK, Fryer HJL, et al. Inhibition of endothelial cell tube formation by ADAMTS13 occurs via interaction with VEGF. Paper presented at: Annual Meeting of the American Society of Hematology; December 6, 2010; San Diego, CA. Abstract 4307.
46. Yamashita T, Kamiya T, Deguchi K, et al. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab 2009; 29: 715-725.
47. Hoang MV, Whelan MC, Senger DR,. Rho activity critically and selectively regulates endothelial cell organization during angiogenesis. Proc Natl Acad Sci U S A 2004; 101: 1874-1879.
48. Miyagi Y, Carpenter RC, Meguro T, et al. Upregulation of rho A and rho kinase messenger RNAs in the basilar artery of a rat model of subarachnoid hemorrhage. J Neurosurg 2000; 93: 471-476.
49. Allen C, Srivastava K, Bayraktutan U,. Small GTPase RhoA and its effector rho kinase mediate oxygen glucose deprivation-evoked in vitro cerebral barrier dysfunction. Stroke 2010; 41: 2056-2063.
50. Wang S, Lee SR, Guo SZ, et al. Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes. Stroke 2006; 37: 1910-1912.